TLC to Present at Upcoming Conferences
SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, April 22, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced that the company’s management team will be presenting at the following conferences:
Date: Friday, April 26, 2019
Time: 11:30am ET
Location: Davis Polk Offices [450 Lexington Avenue, New York, NY]
Dates: Thursday - Sunday, May 2-5, 2019
Location: Sheraton Centre Toronto [123 Queen St W, Toronto, ON M5H 2M9, Canada]
Oral Presentation:
Title: Single Intraarticular Injection of TLC599 Provided Sustained Pain Relief through 24 Weeks in Participants with Symptomatic Knee Osteoarthritis
Presenter: Dr. David Hunter, Professor of Medicine, University of Sydney
Time: 10:05am – 10:15am ET [Sunday, May 5]
Location: Grand Ballroom West
Poster Presentation:
Title: Cartilage Damage and Synovial Toxicokinetic Study of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) following Intraarticular Injection in Healthy Dogs and Rabbits
Number: 204
Presenter: Wan-Ni Yu, PhD, TLC
Time: 4:15pm – 5:00pm ET [Friday, May 3 and Saturday, May 4]
Location: Sheraton Hall / Osgoode & Foyers
Jefferies-Fubon Corporate Access Day
Date: Wednesday, May 15, 2019
Location: Conrad Hong Kong [88 Queensway, Admiralty, Hong Kong]
A copy of the TLC presentation and the poster and oral presentations from OARSI can be accessed by under “News and Events” in the Investors section of TLC’s website at .
About TLC
TLC (Nasdaq: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™). TLC believes that its deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.
Media Contact:
Dawn Chi
Corporate Communications
7 ext. 136
Investor Contact:
Xuan Yang
Solebury Trout
